Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
35.11
+0.50 (1.44%)
At close: Oct 8, 2025, 4:00 PM EDT
35.10
-0.01 (-0.03%)
After-hours: Oct 8, 2025, 4:00 PM EDT
Veracyte Revenue
Veracyte had revenue of $130.16M in the quarter ending June 30, 2025, with 13.75% growth. This brings the company's revenue in the last twelve months to $479.13M, up 19.91% year-over-year. In the year 2024, Veracyte had annual revenue of $445.76M with 23.46% growth.
Revenue (ttm)
$479.13M
Revenue Growth
+19.91%
P/S Ratio
5.62
Revenue / Employee
$581,467
Employees
824
Market Cap
2.76B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 445.76M | 84.71M | 23.46% |
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VCYT News
- 10 days ago - Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer - Business Wire
- 14 days ago - Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 - Business Wire
- 4 weeks ago - Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting - Business Wire
- 5 weeks ago - Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 6 weeks ago - Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer - Business Wire
- 6 weeks ago - Veracyte: Q2 Earnings Brings My Position Out Of Mothballs - Seeking Alpha
- 6 weeks ago - Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test - Business Wire